USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$8.77B
Market Cap
-
P/E Ratio
-1.53
EPS
$203.01
52 Week High
$91.86
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.3B |
| Total Revenue | $4B |
| Cost Of Revenue | $2.7B |
| Costof Goods And Services Sold | $2.7B |
| Operating Income | $227M |
| Selling General And Administrative | $751M |
| Research And Development | - |
| Operating Expenses | $1.1B |
| Investment Income Net | - |
| Net Interest Income | -$118M |
| Interest Income | $8.6M |
| Interest Expense | $126M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $362M |
| Income Before Tax | $93M |
| Income Tax Expense | $68M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $25M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $219M |
| Ebitda | $581M |
| Net Income | $10M |
| Field | Value (USD) |
|---|---|
| Total Assets | $7.5B |
| Total Current Assets | $1.4B |
| Cash And Cash Equivalents At Carrying Value | $195M |
| Cash And Short Term Investments | $195M |
| Inventory | $279M |
| Current Net Receivables | $721M |
| Total Non Current Assets | $6.1B |
| Property Plant Equipment | $2B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $723M |
| Intangible Assets Excluding Goodwill | $723M |
| Goodwill | $2.8B |
| Investments | - |
| Long Term Investments | $218M |
| Short Term Investments | $62K |
| Other Current Assets | $209M |
| Other Non Current Assets | - |
| Total Liabilities | $4B |
| Total Current Liabilities | $994M |
| Current Accounts Payable | $140M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $114M |
| Total Non Current Liabilities | $3B |
| Capital Lease Obligations | $484M |
| Long Term Debt | $2.2B |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $2.7B |
| Other Current Liabilities | $605M |
| Other Non Current Liabilities | $195M |
| Total Shareholder Equity | $3.5B |
| Treasury Stock | - |
| Retained Earnings | $1.8B |
| Common Stock | $511K |
| Common Stock Shares Outstanding | $52M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $735M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $362M |
| Capital Expenditures | $233M |
| Change In Receivables | - |
| Change In Inventory | $17M |
| Profit Loss | - |
| Cashflow From Investment | -$245M |
| Cashflow From Financing | -$551M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$119M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $25M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.3B |
| Total Revenue | $4B |
| Cost Of Revenue | $2.7B |
| Costof Goods And Services Sold | $2.7B |
| Operating Income | $227M |
| Selling General And Administrative | $751M |
| Research And Development | - |
| Operating Expenses | $1.1B |
| Investment Income Net | - |
| Net Interest Income | -$118M |
| Interest Income | $8.6M |
| Interest Expense | $126M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $362M |
| Income Before Tax | $93M |
| Income Tax Expense | $68M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $25M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $219M |
| Ebitda | $581M |
| Net Income | $10M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Charles River Laboratories International, Inc. (CRL) is a leading global provider of critical products and services designed for the pharmaceutical, biotechnology, and medical device industries. The company excels in offering a complete range of preclinical and clinical laboratory services, alongside cutting-edge gene and cell therapy solutions that significantly bolster research and development efforts. With a strong emphasis on innovation and adherence to regulatory standards, Charles River plays a vital role in facilitating efficient drug development processes, thereby contributing to the advancement of healthcare solutions on a global scale.